Asia-Pacific Immunotherapy Drugs Market, by drug type (monoclonal antibodies, interferons, interleukins, vaccines and checkpoint inhibitors), by application (Blood Cancer, Cervical Cancer, Breast Cancer, Glioblastoma, Lung Cancer, Gastric Cancer, Prostate Cancer and Melanoma) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Asia-Pacific Immunotherapy Drugs Market, by drug type (monoclonal antibodies, interferons, interleukins, vaccines and checkpoint inhibitors), by application (Blood Cancer, Cervical Cancer, Breast Cancer, Glioblastoma, Lung Cancer, Gastric Cancer, Prostate Cancer and Melanoma) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1159 | Pages: 129 | November 2016 | Region: Asia Pacific


Asia-Pacific market is currently valued at USD 9.58 billion in 2016 and is poised to reach USD 17.26 billion by 2021 growing at a tremendous CAGR of 12.5% in the forecast period. The usage of the immunotherapy drugs is rising with increasing cancer incidences and autoimmune diseases and is estimated to witness a positive outlook in the forecast period.

Immunotherapy is a process of enhancing your innate power of the immune system to fight against cancer cells. It either counteract the signal which are produced by the cancer cells and suppress the responses by immune system or stimulate the specific components of immune system. These properties of the immunotherapies make them to treat diseases involving infection, cancer, respiratory and autoimmune disorders.

Rising occurrence of cancer and auto immune diseases coupled with the technological advancements has led to innovation of new drugs with the higher efficiency than the existing drugs. Increasing cancer cases with changing demographics, less side effects with higher efficacy, acceleration of drug development process and testing are the primary driving factors for the growth of the market. However, factors including high prices of drugs and less accessibility are dampening the growth of the market.

Asia-Pacific Immunotherapy Drugs are classified based on the type of drugs and by application. Based on the type of drugs, the market is categorised into checkpoint inhibitors, monoclonal antibodies, vaccines, interleukins and interferons. On the basis of application the market is categorised into Cervical Cancer, Lung Cancer, Blood Cancer, Glioblastoma, Breast Cancer, Prostate Cancer, Gastric Cancer and Melanoma. On the basis of geography, Asia-Pacific market is segmented into China, India, Japan, South Korea and Australia.

Some of the major companies in the industry includes Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Seattle Genetics, GlaxoSmithKline PLC, Eli Lilly, Roche, Amgen and Celgene.        

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Immunotherapy Drugs Market By Region, From 2016-2021 (USD Billion)
  2. Asia-Pacific Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  3. Asia-Pacific Monoclonal Antibodies Market By Region, From 2016-2021 (USD Billion)
  4. Asia-Pacific Interferons Market By Region, From 2016-2021 (USD Billion)
  5. Asia-Pacific Interleukins Market By Region, From 2016-2021 (USD Billion)
  6. Asia-Pacific Vaccines Market By Region, From 2016-2021 (USD Billion)
  7. Asia-Pacific Checkpoint Inhibitors Market By Region, From 2016-2021 (USD Billion)
  8. Asia-Pacific Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
  9. Asia-Pacific Blood Cancer Market By Region, From 2016-2021 (USD Billion)
  10. Asia-Pacific Cervical Cancer Market By Region, From 2016-2021 (USD Billion)
  11. Asia-Pacific Breast Cancer Market By Region, From 2016-2021 (USD Billion)
  12. Asia-Pacific Glioblastoma Market By Region, From 2016-2021 (USD Billion)
  13. Asia-Pacific Lung Cancer Market By Region, From 2016-2021 (USD Billion)
  14. Asia-Pacific Gastric Cancer Market By Region, From 2016-2021 (USD Billion)
  15. Asia-Pacific Prostate Cancer Market By Region, From 2016-2021 (USD Billion)
  16. Asia-Pacific Melanoma Market By Region, From 2016-2021 (USD Billion)
  17. China Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  18. China Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
  19. India Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  20. India Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
  21. Japan Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  22. Japan Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
  23. South Korea Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  24. South Korea Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
  25. Australia Immunotherapy Drugs Market By Drug Type, From 2016-2021 (USD Billion)
  26. Australia Immunotherapy Drugs Market By Application, From 2016-2021 (USD Billion)
Middle East and Africa Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, N...
Latin America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gener...
Asia-Pacific Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Genera...
Europe Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation s...
North America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems (CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gene...
Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation sequenci...
Middle East and Africa Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous syste...
Latin America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Asia-Pacific Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, a...
Europe Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-ca...
North America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-cancer dr...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.